Baxter builds EUR 30 million production facility in Vienna

A total of EUR 100 million will be invested by the company in Austria this year. Photo: APA (epa)

The U.S. pharmaceutical group Baxter has laid the foundation for a new production facility in Vienna where biological tissue adhesive for surgical purposes will be manufactured. The investment volume amounts to EUR 30 million. The new building should be put into operation at the end of 2012, according to information supplied by the company.

In 2011 Baxter invested some EUR 47 million in factory equipment. Capital expenditure is expected to reach about EUR 100 million in 2012. The pharmaceutical and biotech company Baxter acquired the Austrian firm Immuno AG in the year 1996, and employs a work force of 4,100 people in Austria today. 116 employees were added in 2011. Baxter has a staff of 50,000 employees worldwide.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)